PATENT CLAIM ANALYSIS

Application Number: 16301027
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-06
Patent Classification: ["514", "254030"]

Abstract:
Provided are a preparation method for a crystalline form of the compound represented by formula (A), as well as a method for preparation thereof, a composition thereof, and an application thereof in preparing an angiotensin II receptor antagonist or an application in preparing a drug for preventing and/or treating hypertension, chronic heart failure and diabetic nephropathy.

Claim (Index 1):
A crystalline form of a compound of formula (A): wherein, the crystalline form comprises one or more selected from the group consisting of: a crystalline form I, a crystalline form II, a crystalline form III and a crystalline form IV, wherein, a X-ray powder diffraction pattern of the crystalline form I comprises characteristic peaks at diffraction angles (2-Theta) of 5.3\u00b10.2\u00b0, 8.6\u00b10.2\u00b0; preferably, the X-ray powder diffraction pattern of the crystalline form I further comprises characteristic peaks at diffraction angles (2-Theta) of 13.3\u00b10.2\u00b0, 20.1\u00b10.2\u00b0; further preferably, the X-ray powder diffraction pattern of the crystalline form I further comprises characteristic peaks at diffraction angles (2-Theta) of 6.3\u00b10.2\u00b0, 10.6\u00b10.2\u00b0, 26.3\u00b10.2\u00b0; more preferably, the X-ray powder diffraction pattern of the crystalline form I further comprises characteristic peaks at diffraction angles (2-Theta) of 12.7\u00b10.2\u00b0; most preferably, the X-ray powder diffraction pattern of the crystalline form I comprises characteristic peaks at diffraction angles (2-Theta) substantially as shown in  FIG. 1 ; a X-ray powder diffraction pattern of the crystalline form II comprises characteristic peaks at diffraction angles (2-Theta) of 4.7\u00b10.2\u00b0; preferably, the X-ray powder diffraction pattern of the crystalline form II further comprises characteristic peaks at diffraction angles (2-Theta) of 7.3\u00b10.2\u00b0, 9.6\u00b10.2\u00b0, 15.2\u00b10.2\u00b0, 26.3\u00b10.2\u00b0; further preferably, the X-ray powder diffraction pattern of the crystalline form II further comprises characteristic peaks at diffraction angles (2-Theta) of 11.8\u00b10.2\u00b0, 24.6\u00b10.2\u00b0; more preferably, the X-ray powder diffraction pattern of the crystalline form II further comprises characteristic peaks at diffraction angles (2-Theta) of 22.6\u00b10.2\u00b0; most preferably, the X-ray powder diffraction pattern of the crystalline form II comprises characteristic peaks at diffraction angles (2-Theta) substantially as shown in  FIG. 2 ; a X-ray powder diffraction pattern of the crystalline form III comprises characteristic peaks at diffraction angles (2-Theta) of 5.2\u00b10.2\u00b0, 8.0\u00b10.2\u00b0; preferably, the X-ray powder diffraction pattern of the crystalline form III further comprises characteristic peaks at diffraction angles (2-Theta) of 12.4\u00b10.2\u00b0, 13.6\u00b10.2\u00b0; further preferably, the X-ray powder diffraction pattern of the crystalline form III further comprises characteristic peaks at diffraction angles (2-Theta) of 19.2\u00b10.2\u00b0; more preferably, the X-ray powder diffraction pattern of the crystalline form III further comprises characteristic peaks at diffraction angles (2-Theta) of 10.3\u00b10.2\u00b0, 12.2\u00b10.2\u00b0, 21.4\u00b10.2\u00b0; most preferably, the X-ray powder diffraction pattern of the crystalline form III comprises characteristic peaks at diffraction angles (2-Theta) substantially as shown in  FIG. 3 ; a X-ray powder diffraction pattern of the crystalline form IV comprises characteristic peaks at diffraction angles (2-Theta) of 7.4\u00b10.2\u00b0, 14.7\u00b10.2\u00b0, 16.0\u00b10.2\u00b0; preferably, the X-ray powder diffraction pattern of the crystalline form IV further comprises characteristic peaks at diffraction angles (2-Theta) of 8.4\u00b10.2\u00b0, 22.6\u00b10.2\u00b0, 23.2\u00b10.2\u00b0, 29.7\u00b10.2\u00b0; more preferably, the X-ray powder diffraction pattern of the crystalline form IV further comprise characteristic peaks at diffraction angles (2-Theta) of 24.0\u00b10.2\u00b0; most preferably, the X-ray powder diffraction pattern of the crystalline form IV comprise characteristic peaks at diffraction angles (2-Theta) substantially as shown in  FIG. 4 .

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.46512
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13001715', '15740719', '13805920', '14116099', '13505360']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8034478749978258
- 35 USC 102 Novelty (BERT): 0.5312104073756073
- Combined Prediction Score: 0.7762241282356039
- Mean Citation Score: 333.132024
- Max Citation Score: 349.10037
- Similarity Product: 297.2907716698265

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test